April 2026

Yambaling Hydropower Limited is set to open its Initial Public Offering (IPO) for the general public from Baishakh 16, 2083. The company will issue 17,43,000 unit shares at a par value of Rs. 100 per share. The early closing date for the IPO is Baishakh 22, 2083, with a possible extension until Baishakh 30, 2083 if the issue remains undersubscribed. Issue Structure The company has an issued capital of Rs. 70 Crores, of which 40% (28,00,000 units) is allocated to the public. Previously, 10% (7,00,000 units) was distributed to project-affected locals of Sindhupalchok District. The remaining 30% (21,00,000 units) is allocated to the general public, divided as follows: Investors can apply for a minimum of 10 units and a maximum of 21,000 units. The issue manager for the IPO is Muktinath Capital Limited. The company has received an issuer rating of CARE-NP BB- (Is) from CARE Ratings Nepal Limited, indicating a moderate risk of default in meeting financial obligations. About the Company Established in 2007 and converted into a public company in 2021, Yambaling Hydropower operates the 7.27 MW Yambaling Khola Hydropower Project in Sindhupalchok. The project commenced commercial operation on February 20, 2024, under the BOOT (Build, Own, Operate, Transfer) model.

NIC Asia Laghubitta Bittiya Sanstha Limited (NICLBSL) has announced that it will not distribute any dividend for the fiscal year 2081/82. The decision was made during the company’s 263rd Board of Directors meeting held on Baisakh 04, 2083. According to the company, the move is subject to approval of its financial statements by Nepal Rastra Bank and endorsement at the upcoming Annual General Meeting (AGM). As of the latest market update, shares of NICLBSL were traded at Rs. 590.00.

Sopan Pharmaceuticals Limited is set to open its Initial Public Offering (IPO) for the general public from 3rd Baishakh to 8th Baishakh, 2083. The company will issue 34,74,900 units IPO Shares to the general public at a face value of Rs. 100 per share. If the issue is not fully subscribed within the early closing period, the deadline will be extended until 17th Baishakh, 2083. Sopan Pharmaceuticals has an issued capital of Rs. 1.71 Arba, of which 25 percent, or 42,90,000 units, has been allocated for the public offering. Out of the total shares, 10 percent (4,29,000 units) has been already issued to Nepali citizens working abroad, 4 percent (1,71,600 units) to employees, and 5 percent (2,14,500 units) to mutual funds. The remaining 34,74,900 units have been made available for the general public. According to CARE Ratings Nepal Limited, the company holds an issuer rating of CARE-NP B (Is). The long-term bank facility rating stands at CARE-NP B, while the short-term rating is CARE-NP A4. These ratings indicate a high risk of default. The IPO is being managed by NMB Capital Limited. Investors can apply for a minimum of 10 units and a maximum of 11,000 units. Applications for the IPO can be submitted through MeroShare and authorized financial institutions within the specified period. About the Company Sopan Pharmaceuticals Limited is a WHO-GMP, National GMP, and ISO 9001:2015 certified pharmaceutical company based in Lalitpur. Promoted by Sopan Multiple Company Limited, it began commercial production in 2078 B.S. and manufactures a range of medicines under strict cGMP standards. The company focuses on delivering safe, effective, and affordable pharmaceutical products, supported by strong capabilities in production, quality control, and research and development.